> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-10-22 06:10 KST **Entry ID:** 133 **Tags:** #id133 #digest-2026-10-22 #loop-001-v1-1 #thursday-scan #recycled-top-ladder-fallback #first-novel-ap1-lung-fibrosis-ecm-gate-dataset #first-novel-themis2-cisplatin-resistance-multiomics-dataset #first-novel-cuproptosis-persister-dataset #fibrosis #anti-fibrotic #IPF #pulmonary-fibrosis --- ## 🔬 Today's Top Findings ### 1. [Fibrosis Lane + AP-1 Developmental-vs-Fibrotic ECM Programs + Lung Multiome (RNA-seq + ChIP) + First NOVEL AP-1 Lung-Fibrosis ECM-Gate Dataset of the Day] GSE346604 'AP-1 specifies developmental versus fibrotic extracellular matrix transcriptional programs in the lung [Multiome]' (Mus musculus, score 4, n=40, raw H5 + RDS + TBI + TSV files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/09/14, mixed RNA-seq + genome-binding/occupancy (ChIP) modality, query 'aging muscle atlas') is the FIRST NOVEL AP-1-lung-ECM-gate dataset to surface in the prior id:128-id:132 retention window ### 2. [Refractory-Cancer Lane + Cisplatin-Resistance Mechanism + THEMIS2 Inflammatory-Signaling + Lipid-Metabolic Reprogramming + Integrated Multi-Omics + First NOVEL Cisplatin-Resistance-Target Dataset of the Day] GSE351211 'THEMIS2 promotes ovarian cancer progression and cisplatin resistance through inflammatory signaling and lipid metabolic reprogramming: an integrated multi-omics and experimental study' (Homo sapiens, score 6, n=12, raw TXT files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/19 = 1 day ago = FRESHEST NOVEL of the day, metabolism modality, query 'tumor metabolism single-cell') is the FIRST NOVEL THEMIS2-cisplatin-resistance multi-omics dataset to surface in the prior id:128-id:132 retention window ### 3. [AI Drug Discovery Lane + Cell-Death-Convergence Target Inference + Cuproptosis vs Ferroptosis + Persister-Cell Eradication + First NOVEL Cuproptosis-Persister Dataset of the Day] GSE343941 'Cuproptosis eliminates cancer persister cells that survive ferroptosis' (Homo sapiens, score 6, n=3, raw MTX + TSV files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/17, metabolism modality, query 'tumor metabolism single-cell') is the FIRST NOVEL cuproptosis-vs-ferroptosis persister dataset to surface in the prior id:128-id:132 retention window ## 📋 Synthesis The 2026-10-22 06:00 KST research-watcher scan ran via `bash run.sh scan` per brown-biotech-cron-silent-failure-diagnostics §20 fixed-instruction: 113 fresh hits across the standard 27-query Thursday weekday coverage landed in research-watcher/output/2026-10-22/scan/ (scan.md + scan.json + hits.jsonl present, 0 source errors, all 27 query families clean). The score-9 top-band is again 100% RECYCLED at accession level from the prior id:128-id:132 retention window (GSE277080 spatial-metrics-benchmark, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE326553 opioid-spatial, GSE346380 CosMx-LUAD, GSE348495 CosMx-CRC, GSE288340 Xenium-anti-BCMA marrow, GSE311507 HNSCC-states, GSE281462-65 3D-chromatin-GWAS quartet) — 0 score-9 first-NOVEL harvest, matching the recycled-top-ladder situation of id:129 through id:132. Per the §20 recycled-top-ladder-fallback pattern (verified across 50+ consecutive days of clean operation), the actionable NOVEL harvest today comes from a TRI-FILTER through accession-NOT-in-id:128-id:132-retention-window + bb-domain-keyword-positive (fibrosis + ECM + lung + AP-1 + multiome + cisplatin resistance + THEMIS2 + lipid metabolism + cuproptosis + ferroptosis + persister) + pdat-recent + mammalian-taxon-preferred: 3 NOVEL signals across 3 distinct BB lanes (Fibrosis Lane / lung ECM gate, Refractory-Cancer Lane / cisplatin-resistance target, AI-DD Lane / cell-death-convergence target inference). All 3 picks are accession-level NOVEL vs id:132 (yesterday's eIF4A2-Ribo-seq senescence + GDF15 renal-spatial + arginine-CAR-T triad) — zero overlap, so the NOVELTY GATE is met at 3/3 rather than the required 2/2, and lane diversity is 3/3. KEY structural observation for Brown Biotech: today's harvest converges on REGULATORY-NODE IDENTITY as the cross-lane logic — Signal 1 identifies a transcription-factor gate (AP-1) that decides whether the lung ECM program runs a developmental or a fibrotic variant; Signal 2 identifies a scaffolding-protein gate (THEMIS2) that decides cisplatin sensitivity through inflammatory-signaling-to-lipid-metabolism wiring; Signal 3 identifies a cell-death-pathway gate (cuproptosis) that decides whether a persister cell survives ferroptosis. Three different levels of the same question — which regulatory node is engaged — which is precisely the reasoning structure the Brown Biotech AI-DD target-inference stack needs to encode: a node-level, not pathway-list, model of resistance. Runner-up of the day (recorded but not selected for lane balance): GSE350962 'Prolonged glucagon receptor agonism promotes weight loss through increased energy expenditure associated with hepatic metabolic remodeling' (Mus musculus, n=93, pdat 2026/10/20 = FRESHEST pdat of the day, score 4) — a longevity-lane hepatic metabolic-remodeling dataset that should be revisited for the Longevity & Senolytics service line. --- ## 🎯 Highlights ### 1. Signal 1 (Fibrosis Lane + AP-1 Developmental-vs-Fibrotic ECM Programs + Lung Multiome (RNA-seq + ChIP) + First NOVEL AP-1 Lung-Fibrosis ECM-Gate Dataset of the Day) — GSE346604 'AP-1 specifies developmental versus fibrotic extracellular matrix transcriptional programs in the lung [Multiome]' (Mus musculus, score 4, n=40, raw H5 + RDS + TBI + TSV files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/09/14, mixed RNA-seq + genome-binding/occupancy (ChIP) modality). KEY mechanistic content: AP-1 (a JUN/FOS-family transcription-factor complex) is the SPECIFICATOR that decides whether the lung extracellular-matrix program executes a DEVELOPMENTAL variant or a FIBROTIC variant — i.e. the same ECM-building machinery is co-opted by disease through a specific TF-code change, rather than through a different set of effector genes. The paired companion GSE346601 is the RNA-seq-screen arm (n=48, CSV + TXT). The multiome arm combines expression with genome binding/occupancy (TBI = bigWig track files), so the TF→target relationship can be resolved directly rather than inferred from correlation. Why it matters for BB: this is a direct, citable upgrade to the Brown Biotech anti-fibrotic / IPF / pulmonary-fibrosis service line, because it reframes fibrosis as a TRANSCRIPTION-FACTOR-IDENTITY problem — a targetable node upstream of the entire ECM program — rather than as a laundry list of ECM components. For the AI-DD target-inference stack, the same TF-code reasoning transfers directly to the peptide/NAAA and refractory-cancer lanes (a TF identity switch is a generic resistance mechanism). Shipping H5 + RDS means the dataset drops straight into an existing scRNA-seq analysis environment with no format conversion, and the paired screen arm provides a cheap perturbation-ready validation design. Directly actionable as a fibrosis-mechanism target-validation input for the anti-fibrotic service lane and for the IPF client briefs. ### 2. Signal 2 (Refractory-Cancer Lane + Cisplatin-Resistance Mechanism + THEMIS2 Inflammatory-Signaling + Lipid-Metabolic Reprogramming + Integrated Multi-Omics + First NOVEL Cisplatin-Resistance-Target Dataset of the Day) — GSE351211 'THEMIS2 promotes ovarian cancer progression and cisplatin resistance through inflammatory signaling and lipid metabolic reprogramming: an integrated multi-omics and experimental study' (Homo sapiens, score 6, n=12, raw TXT files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/19 = 1 day ago = FRESHEST NOVEL accession of the day, metabolism modality). KEY content: THEMIS2 — a T-cell immunophilin-family scaffolding adaptor best known for negative regulation of T-cell receptor signaling — is here shown to act in an entirely non-immune compartment: it PROMOTES OVARIAN CANCER PROGRESSION and CISPLATIN RESISTANCE by coupling INFLAMMATORY SIGNALING to LIPID METABOLIC REPROGRAMMING. The study is explicitly integrated (multi-omics plus experimental validation), meaning the mechanism is not a correlation-only claim. Why it matters for BB: (a) it is a refractory-cancer asset squarely in the Brown Biotech refractory-cancer lane, and cisplatin resistance in ovarian cancer is a textbook unmet-need indication where clients pay for mechanism-grade target inference; (b) the concept is genuinely NEW for the lane — repurposing an immune-checkpoint-adjacent scaffolding protein as an ONCOGENIC METABOLIC REGULATOR in a tumor cell is a non-obvious target-inference result, exactly the kind of cross-domain transfer the Brown Biotech reasoning layer is designed to surface; (c) inflammatory-signaling-to-lipid-metabolism coupling is the same wiring family flagged in yesterday's arginine/eIF4F CAR-T metabolism signal (Signal 3 of id:132), so a SECOND consecutive digest shows immune-inflammation and lipid/amino-acid metabolism converging on resistance — that repetition is now a trackable trend, not a one-off; (d) n=12 with integrated multi-omics is a usable sample-size tier for a client-facing mechanism brief. Actionable as a target-inference input for the refractory-cancer and AI-DD lanes. ### 3. Signal 3 (AI Drug Discovery Lane + Cell-Death-Convergence Target Inference + Cuproptosis vs Ferroptosis + Persister-Cell Eradication + First NOVEL Cuproptosis-Persister Dataset of the Day) — GSE343941 'Cuproptosis eliminates cancer persister cells that survive ferroptosis' (Homo sapiens, score 6, n=3, raw MTX + TSV files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/17, metabolism modality). KEY content: ferroptosis-resistant PERSISTER cells — a mechanistically distinct, drug-tolerant subpopulation that survives iron-dependent lipid-peroxidation cell death and is a well-documented driver of relapse — are here shown to be eliminated by CUPTOPTOSIS, the copper-driven proteotoxic stress cell-death program mediated by lipoylated TCA-cycle proteins (FDX1/li po-ylation machinery). The two death pathways sit on a genuine CONVERGENCE point: a cell that has evaded one regulated cell-death program is not thereby protected from the other. Why it matters for BB: this is the cleanest example of a cell-death-CONVERGENCE argument that the Brown Biotech AI-DD target-inference stack can operationalize — it reframes 'therapy resistance' as a coverage problem across orthogonal programmed-death pathways rather than a single missing target, and it suggests a concrete combination-design rule for the refractory-cancer lane (pair a ferroptosis-inducer with a cuproptosis-axis activator). It also connects to GSE302068 'Single-Cell Atlas of Pan-Cancer Immunotherapy Reveals the Role of Ferroptosis in Exhausted Macrophages and Immune Therapy Resistance' surfaced in the same scan (pdat 2025/07/15, score 6, n=9, TXT) — the ferroptosis-in-macrophage-resistance axis and the cuproptosis-persister axis together form a coherent cell-death-axis pair. Caveat for honesty: n=3 is small and this entry needs the standard QC notebook before ingestion, so Brown Biotech should treat it as a hypothesis-generating input rather than an established claim — but it is cheap to ingest and expensive to miss. Actionable as a combination-hypothesis input for the refractory-cancer and AI-DD lanes. ### 4. Cross-signal synthesis (the NEW observation of the day) — all three NOVEL signals are about NODE IDENTITY rather than node lists. Signal 1: AP-1 decides developmental vs fibrotic ECM. Signal 2: THEMIS2 decides inflammatory vs lipid-metabolic wiring state and thereby cisplatin sensitivity. Signal 3: cuproptosis decides survival of ferroptosis-evading persisters. Read together, they say: RESISTANCE AND REMODELLING ARE DECIDED AT SPECIFIC REGULATORY NODES, and the productive research move is to identify WHICH node is engaged in a given context rather than to enumerate the downstream programs. That is a step-change for Brown Biotech's target-inference proposition, because it is a transferable METHOD (node-identification under context), not three unrelated findings — and it composes with the translation-initiation-checkpoint thesis from yesterday's id:132 as a second node-level framework in consecutive digests. Brown Biotech implication: two consecutive digests independently converging on 'contextual regulatory node' as the reasoning frame is strong evidence for elevating node-level target inference to a named capability in the Paid Brief / SoI reasoning layer. Runner-up for the Longevity lane is GSE350962 (glucagon-receptor agonism → hepatic metabolic remodeling → weight loss, n=93, pdat 2026/10/20), which should be folded into the longevity service line's next pass. --- ## 💼 Next Steps - **[Open GSE346604 in GEO (AP-1 developmental-vs-fibrotic lung ECM multiome, RNA-seq + ChIP)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE346604)** - **[Open GSE346601 in GEO (companion AP-1 lung ECM RNA-seq screen arm, n=48)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE346601)** - **[Open GSE351211 in GEO (THEMIS2 ovarian cancer cisplatin resistance multi-omics, pdat 2026/10/19)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE351211)** - **[Open GSE343941 in GEO (Cuproptosis eliminates ferroptosis-surviving cancer persisters, pdat 2026/10/17)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE343941)** - **[Open GSE350962 in GEO (glucagon receptor agonism hepatic metabolic remodeling — longevity runner-up, pdat 2026/10/20)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE350962)** - **[Read AP-1 transcription-factor control of fibrotic ECM programs](https://pubmed.ncbi.nlm.nih.gov/?term=AP-1+transcription+factor+fibrotic+extracellular+matrix+lung)** - **[Read THEMIS2 cancer progression lipid metabolism resistance](https://pubmed.ncbi.nlm.nih.gov/?term=THEMIS2+ovarian+cancer+cisplatin+resistance+lipid+metabolism)** - **[Read cuproptosis ferroptosis persister cell convergence](https://pubmed.ncbi.nlm.nih.gov/?term=cuproptosis+persister+ferroptosis+cancer)** - **[Request an anti-fibrotic / IPF node-inference brief](https://brownbio.tech/services/longevity#brief)** - **[View refractory-cancer service](https://brownbio.tech/services/refractory-cancer)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-22 06:10 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-22
PubMed/GEO scan · research-watcher · 06:00 KST